11 active not recruiting. 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 11 |
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma Elranatamab - Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 50 | 2024-05-14 | 2026-09-02 |
| Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy Zanubrutinib Oral Product - Monoclonal Gammopathy of Uncertain Significance | Phase 2 | Active not recruiting | UMC Utrecht | 35 | 2024-03-01 | 2026-05-08 |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Linvoseltamab - Smoldering Multiple Myeloma (SMM) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 40 | 2024-01-30 | 2026-04-13 |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2023-04-19 | 2026-03-12 |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Cholestyramine, Leflunomide - Smoldering Plasma Cell Myeloma | Phase 2 | Active not recruiting | City of Hope Medical Center | 27 | 2022-03-07 | 2026-04-30 |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Metformin XR, Placebo - Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 60 | 2021-04-27 | 2026-02-09 |
| Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM Carfilzomib, Dexamethasone, Lenalidomide - Smouldering Myeloma | Phase 2 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 58 | 2018-11-19 | 2023-11-01 |
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant Carfilzomib, Lenalidomide, Daratumumab - Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | International Myeloma Foundation | 87 | 2018-05-25 | 2023-12-12 |
| Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Daratumumab - Monoclonal Gammopathy, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 42 | 2017-11-24 | 2026-03-27 |
| Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) Isatuximab, Laboratory Biomarker Analysis - Smoldering Plasma Cell Myeloma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 61 | 2017-02-08 | 2026-10-06 |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma carfilzomib, Lenalidomide, Dexamethasone - Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | PETHEMA Foundation | 90 | 2015-05-01 | 2022-09-10 |
Smoldering Multiple Myeloma (10) · Monoclonal Gammopathy of Undetermined Significance (2) · Multiple Myeloma (2) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1)
Blood Protein Disorders (11) · Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Neoplasms (10) · Paraproteinemias (10) · Precancerous Conditions (10) · Neoplasms by Histologic Type (3) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms, Plasma Cell (2)
Dexamethasone (3) · Lenalidomide (3) · carfilzomib (3) · daratumumab (2) · Cholestyramine Resin (1) · Cyclophosphamide (1) · Leflunomide (1) · Melphalan (1) · Metformin (1) · fludarabine (1) · fludarabine phosphate (1) · isatuximab (1)
Dana-Farber Cancer Institute (3) · City of Hope Medical Center (1) · European Myeloma Network B.V. (1) · International Myeloma Foundation (1) · M.D. Anderson Cancer Center (1) · PETHEMA Foundation (1) · Regeneron Pharmaceuticals (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · UMC Utrecht (1)
United States (6) · Netherlands (3) · Italy (2) · Norway (2) · Spain (2) · Czechia (1) · France (1)
Irene Ghobrial, MD (2) · A. Broijl (1) · Brian Durie, MD (1) · Catherine R Marinac, PhD (1) · Michael A Rosenzweig (1) · Omar Nadeem, MD (1) · Shaji Kumar, MD (1) · Sheeba Thomas, MD (1)
PMID 38988266, PMID 39038268, PMID 42010117
2017 (1), 2023 (1), K22CA251648 (1), P30CA033572 (1)